366 related articles for article (PubMed ID: 31102185)
21. Specific increase in MDR1 mediated drug-efflux in human brain endothelial cells following co-exposure to HIV-1 and saquinavir.
Roy U; Bulot C; Honer zu Bentrup K; Mondal D
PLoS One; 2013; 8(10):e75374. PubMed ID: 24098380
[TBL] [Abstract][Full Text] [Related]
22. HIV-1 Tat and Morphine Differentially Disrupt Pyramidal Cell Structure and Function and Spatial Learning in Hippocampal Area CA1: Continuous versus Interrupted Morphine Exposure.
Marks WD; Paris JJ; Barbour AJ; Moon J; Carpenter VJ; McLane VD; Lark ARS; Nass SR; Zhang J; Yarotskyy V; McQuiston AR; Knapp PE; Hauser KF
eNeuro; 2021; 8(3):. PubMed ID: 33782102
[TBL] [Abstract][Full Text] [Related]
23. Protective Effects of Ginsenoside Rb1 against Blood-Brain Barrier Damage Induced by Human Immunodeficiency Virus-1 Tat Protein and Methamphetamine in Sprague-Dawley Rats.
Li J; Zeng B; Hu X; Li Z; Zhang D; Yang G; Dai J; Zeng X
Am J Chin Med; 2018; 46(3):551-566. PubMed ID: 29690789
[TBL] [Abstract][Full Text] [Related]
24. Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults.
Singh RP; Shaik JSB; Skoura N; Joshi S; Shreeves T; Casillas L; Buchanan AM
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):631-638. PubMed ID: 30239425
[TBL] [Abstract][Full Text] [Related]
25. Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man.
van Dam PM; van Geffen MW; Havenith TR; Posthouwer D
Antivir Ther; 2018; 23(6):549-552. PubMed ID: 29533918
[TBL] [Abstract][Full Text] [Related]
26. Myelin regulatory factor is a target of individual and interactive effects of HIV-1 Tat and morphine in the striatum and pre-frontal cortex.
Flounlacker KM; Hahn YK; Xu R; Simons CA; Tian T; Hauser KF; Knapp PE
J Neurovirol; 2023 Feb; 29(1):15-26. PubMed ID: 36853588
[TBL] [Abstract][Full Text] [Related]
27. Tat 101-mediated enhancement of brain pericyte migration involves platelet-derived growth factor subunit B homodimer: implications for human immunodeficiency virus-associated neurocognitive disorders.
Niu F; Yao H; Zhang W; Sutliff RL; Buch S
J Neurosci; 2014 Aug; 34(35):11812-25. PubMed ID: 25164676
[TBL] [Abstract][Full Text] [Related]
28. Central HIV-1 Tat exposure elevates anxiety and fear conditioned responses of male mice concurrent with altered mu-opioid receptor-mediated G-protein activation and β-arrestin 2 activity in the forebrain.
Hahn YK; Paris JJ; Lichtman AH; Hauser KF; Sim-Selley LJ; Selley DE; Knapp PE
Neurobiol Dis; 2016 Aug; 92(Pt B):124-36. PubMed ID: 26845176
[TBL] [Abstract][Full Text] [Related]
29. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.
Bollen P; Reiss P; Schapiro J; Burger D
Expert Opin Drug Saf; 2015; 14(9):1457-72. PubMed ID: 26134478
[TBL] [Abstract][Full Text] [Related]
30. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food.
Weller S; Chen S; Borland J; Savina P; Wynne B; Piscitelli SC
J Acquir Immune Defic Syndr; 2014 Aug; 66(4):393-8. PubMed ID: 24798770
[TBL] [Abstract][Full Text] [Related]
31. Morphine efficacy is altered in conditional HIV-1 Tat transgenic mice.
Fitting S; Scoggins KL; Xu R; Dever SM; Knapp PE; Dewey WL; Hauser KF
Eur J Pharmacol; 2012 Aug; 689(1-3):96-103. PubMed ID: 22659585
[TBL] [Abstract][Full Text] [Related]
32. Signatures of HIV-1 subtype B and C Tat proteins and their effects in the neuropathogenesis of HIV-associated neurocognitive impairments.
Williams ME; Zulu SS; Stein DJ; Joska JA; Naudé PJW
Neurobiol Dis; 2020 Mar; 136():104701. PubMed ID: 31837421
[TBL] [Abstract][Full Text] [Related]
33. Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro.
Gurwell JA; Nath A; Sun Q; Zhang J; Martin KM; Chen Y; Hauser KF
Neuroscience; 2001; 102(3):555-63. PubMed ID: 11226693
[TBL] [Abstract][Full Text] [Related]
34. Peptide derived from HIV-1 TAT protein destabilizes a monolayer of endothelial cells in an in vitro model of the blood-brain barrier and allows permeation of high molecular weight proteins.
Cooper I; Sasson K; Teichberg VI; Schnaider-Beeri M; Fridkin M; Shechter Y
J Biol Chem; 2012 Dec; 287(53):44676-83. PubMed ID: 23150670
[TBL] [Abstract][Full Text] [Related]
35. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs.
Rao KS; Reddy MK; Horning JL; Labhasetwar V
Biomaterials; 2008 Nov; 29(33):4429-38. PubMed ID: 18760470
[TBL] [Abstract][Full Text] [Related]
36. Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons.
Fitting S; Xu R; Bull C; Buch SK; El-Hage N; Nath A; Knapp PE; Hauser KF
Am J Pathol; 2010 Sep; 177(3):1397-410. PubMed ID: 20651230
[TBL] [Abstract][Full Text] [Related]
37. Human immunodeficiency virus-1 Tat exerts its neurotoxic effects by downregulating Sonic hedgehog signaling.
Khan IA; Worrad AH; Singh MV; Maggirwar SB; Singh VB
J Neurovirol; 2022 Apr; 28(2):305-311. PubMed ID: 35181862
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells.
András IE; Pu H; Deli MA; Nath A; Hennig B; Toborek M
J Neurosci Res; 2003 Oct; 74(2):255-65. PubMed ID: 14515355
[TBL] [Abstract][Full Text] [Related]
39. Morphine and HIV-1 Tat interact to cause region-specific hyperphosphorylation of tau in transgenic mice.
Ohene-Nyako M; Nass SR; Hahn YK; Knapp PE; Hauser KF
Neurosci Lett; 2021 Jan; 741():135502. PubMed ID: 33202259
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory Control Deficits Associated with Upregulation of CB
Jacobs IR; Xu C; Hermes DJ; League AF; Xu C; Nath B; Jiang W; Niphakis MJ; Cravatt BF; Mackie K; Mukhopadhyay S; Lichtman AH; Ignatowska-Jankowska BM; Fitting S
J Neuroimmune Pharmacol; 2019 Dec; 14(4):661-678. PubMed ID: 31372820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
